Mental health unicorn valued at $4.8B. DEA investigation into ADHD prescriptions. CEO resigned. Staff fled. Mission-washing doesn't survive a federal investigation.
Evaluating only Cerebral’s profile at its peak — without knowing the outcome — the model ranked Unit economics as the #1 likely cause. Documented cause: Regulation.
Key Events Timeline
FOUNDING
Cerebral founded
FOUNDING
Cerebral founded
REGULATORY ACTION
Regulatory pressure escalates
SHUTDOWN
Mass Layoff Spiral: Cerebral ceases operations
CEO CHANGE
CEO resigned; 90% workforce cut; sold therapy business for scraps
SHUTDOWN
Slow Death: Cerebral ceases operations
Full Analysis
Free · no account needed
Documented cause
Cerebral raised $300M at a $4.8B valuation to democratize access to mental health care through telepsychiatry. The company grew explosively by offering easy ADHD diagnoses and stimulant prescriptions via telehealth. In 2022, NBC News investigations and a DOJ/DEA probe found evidence that Cerebral's prescribing practices may have violated the Controlled Substances Act. CEO Kyle Robertson resigned, major pharma partners withdrew, platforms removed Cerebral ads, and the company laid off 15% of staff — all within weeks.
Lesson
“Telehealth businesses prescribing Schedule II controlled substances (Adderall, Ritalin) need compliance-first architectures built before the first prescription. Regulatory risk is existential in this space.”